This digital document is an article from Momentum, published by National Multiple Sclerosis Society on March 22, 2011. The length of the article is 384 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: MS research: the society’s commitment. Author: Unavailable Publication: Momentum (Magazine/Journal) Date: Marc
News Flash: July 31, 2008 – The National(US)Multiple Sclerosis Society has recognized the healing benefits of Cannabis for MS patients! www.norml.org September, 2003 – Joining Multiple Sclerosis patients who use Cannabis (marijuana) to relieve their suffering, Paul Armentano of NORML (source for the above news item) presents research showing that Cannabis has efficacy for the pain and muscle spasticity of MS. In addition, Paul cites evidence that Cannabis and Cannabinoids can actually slow the progress of the disease. Polls among MS patients show that almost half use Cannabis to ease their plight. For more information from Paul Armentano and the National Organization for the Reform of Marijuana Laws: norml.org Visit the Multiple Sclerosis Patients Union mspu.org
This digital document is an article from The Canadian Journal of Human Sexuality, published by SIECCAN, The Sex Information and Education Council of Canada on September 22, 2002. The length of the article is 474 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
This digital document is an article from Momentum, published by National Multiple Sclerosis Society on June 22, 2010. The length of the article is 463 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: Eric Hovde brings investment thinking to the MS research effort.(Face Time)(Fast Forward initiative by National Multiple
Multiple Sclerosis (MS) is an inflammatory disease of the Central Nervous System (CNS) – that’s the brain and spinal cord. Predominantly, it is a disease of the “white matter” tissue. The white matter is made up of nerve fibres which are responsible for transmitting communication signals both internally within the CNS and between the CNS and the nerves supplying rest of the body. In people affected by MS, patches of damage called plaques or lesions appear in seemingly random areas of the CNS white matter. At the site of a lesion, a nerve insulating material, called myelin, is lost. I shall explain this process in more detail later. Clinically, MS is a hard condition to characterise because it is very unpredictable and variable. Depending on which areas of the CNS are affected and how badly they are damaged, the type and severity of symptoms can vary greatly. No two people get MS in exactly the same way and the expression of each individual’s disease is as unique as their fingerprints. However, the different courses of the disease, both within an individual and within the whole population, principally differ in their timing, location and severity. Underneath similar processes (including demyelination and sometimes other forms of nerve degeneration) are going on. Although recent research indicates that the biochemical make-up of lesions may vary between different forms of the disease, this is not the reason why people with MS (PwMS) have such widely differing symptoms …
Multiple Sclerosis (MS) is an inflammatory disease of the Central Nervous System (CNS) – that’s the brain and spinal cord. Predominantly, it is a disease of the “white matter” tissue. The white matter is made up of nerve fibres which are responsible for transmitting communication signals both internally within the CNS and between the CNS and the nerves supplying rest of the body. In people affected by MS, patches of damage called plaques or lesions appear in seemingly random areas of the CNS white matter. At the site of a lesion, a nerve insulating material, called myelin, is lost. I shall explain this process in more detail later. Clinically, MS is a hard condition to characterise because it is very unpredictable and variable. Depending on which areas of the CNS are affected and how badly they are damaged, the type and severity of symptoms can vary greatly. No two people get MS in exactly the same way and the expression of each individual’s disease is as unique as their fingerprints. However, the different courses of the disease, both within an individual and within the whole population, principally differ in their timing, location and severity. Underneath similar processes (including demyelination and sometimes other forms of nerve degeneration) are going on. Although recent research indicates that the biochemical make-up of lesions may vary between different forms of the disease, this is not the reason why people with MS (PwMS) have such widely differing symptoms …